Samotolisib - Eli Lilly and Company
Alternative Names: LY 3023414Latest Information Update: 05 Nov 2023
At a glance
- Originator Eli Lilly and Company; Sarah Cannon Research Institute
- Developer Eli Lilly and Company; Memorial Sloan-Kettering Cancer Center
- Class Antineoplastics; Imidazoles; Pyridines; Quinolines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; DNA-activated protein kinase inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Most Recent Events
- 21 Apr 2022 Eli Lilly completes a phase I trial in cancer (Late-stage disease, Second-line therapy or greater) in USA (NCT01655225)
- 23 Mar 2022 Eli Lilly and Company completes a phase II trial in Endometrial cancer (Second-line therapy or greater) in USA (NCT02549989)
- 17 Apr 2020 Eli Lilly completes a phase II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (PO) (NCT02407054)